Cellectis (CLLS) Other Non-Current Liabilities (2014 - 2026)
Cellectis (CLLS) recorded quarterly Other Non-Current Liabilities of $1.3 million in Q1 2026, little changed quarter-over-quarter from $1.3 million in Q4 2025, and up 16.24% on a YoY basis from $1.1 million in Q1 2025.
Cellectis (CLLS) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Cellectis' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 16.24% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 16.24% YoY), while the FY2025 annual figure was $1.3 million, up 19.19% from the prior year.
- Other Non-Current Liabilities was $1.3 million for Q1 2026 at Cellectis, roughly flat from $1.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.7 million in Q1 2022 to a low of $1.1 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $2.1 million across 5 years, with a median of $2.2 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities soared 281.79% in 2022, then plunged 49.32% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $2.4 million in 2022, then dropped by 7.95% to $2.2 million in 2023, then slumped by 49.32% to $1.1 million in 2024, then rose by 19.19% to $1.3 million in 2025, then retreated by 0.38% to $1.3 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.32 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 2.19 Mn |
| Mar 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Sep 30, 2023 | 2.56 Mn |
| Jun 30, 2023 | 2.64 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 2.85 Mn |
| Mar 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 626,000.00 |
| Sep 30, 2021 | 3.85 Mn |
| Jun 30, 2021 | 3.61 Mn |